111108 ⎘
ssRNA viruses negative-sense; Details; Rhabdoviridae; Vesiculovirus, e.g. vesicular stomatitis Indiana virus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY
#2SELF-REPLICATING RNA VACCINES AND METHODS OF USE
#3MODIFIED VARICELLA ZOSTER VIRUS GLYCOPROTEIN E PROTEINS
#4MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS
#5ALUMINUM NANOCRYSTAL DELIVERY SYSTEM, AND SELF-ASSEMBLED PARTICLE ADJUVANT VACCINE BASED ON BINDING OF ALUMINUM NANOCRYSTAL DELIVERY SYSTEM AND VACCINE ANTIGEN MOLECULE
#6RECOMBINANT LIVE ATTENUATED RSV VACCINE STRAIN AND PRODUCTION METHOD THEREFOR
#7Viral Vaccines
#8VERSATILE VIRUS-LIKE-VESICLES (VLV) PLATFORM FOR INFECTIOUS DISEASES AND CANCER IMMUNOTHERAPY APPLICATIONS
#9MULTIVALENT VIRAL PARTICLES
#10Vaccine Compositions For Preventing Coronavirus Disease
#11COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION
#12SYNTHETIC DNA VACCINE IMMUNOGENIC IMPROVEMENTS
#13METHOD FOR INFECTING CELLS WITH VIRUS
#14ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY
#15COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUS
#16ONCOLYTIC VIRUS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS
#17BLOCKADE OF IFN SIGNALING DURING CANCER VACCINATION
#18Method for infecting cells with virus
#19Compositions and methods for viral sensitization
#20METHOD FOR VIRUS PRODUCTION
#21Vaccine compositions for the treatment of coronavirus
#22Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins
#23NUCLEOTIDE VACCINE
#24Recombinant viral vectors
#25Activation of resident memory T cells for cancer immunotherapy
#26Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
#27Compositions and methods for viral sensitization
#28MODIFIED VSV-G AND VACCINES THEREOF
#29Zika virus vaccine
#30Recombinant viral vectors
#31Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
#32Activation of resident memory T cells for cancer immunotherapy
#33Compositions and methods for viral sensitization
#34Compositions and methods for treatment of cytomegalovirus
#35Recombinant viral vectors
#36Protein muNS that can form inclusions in the endoplasmic reticulum, methods for the use thereof and uses of same
#37Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins
#38Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins
#39Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins
#40Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
#41ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#42Recombinant viral vectors
#43Modified matrix proteins of vesicular stomatitis virus
#44COMPOSITIONS AND METHODS OF MODULATING AN IMMUNE RESPONSE
#45Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#46Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins
#47Norovirus immunogens and related materials and methods
#48Compositions and methods for treatment of cytomegalovirus
#49Immunization compositions and methods
#50HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF
#51METHODS AND COMPOSITIONS FOR THE PRODUCTION OF RECOMBINANT VIRUS VECTORS
#52Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#53IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES
#54Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
#55Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
#56Methods and compositions for the production of recombinant virus vectors
#57Immunization compositions and methods
#58LENTIVIRUS-BASED IMMUNOGENIC VECTORS
#59Human antibodies against rabies and uses thereof
#60NUCLEOTIDE VACCINE
#61Mutant viruses and uses thereof
#62NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES
#63RECOMBINANT VIRAL VECTORS
#64Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
#65ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#66Signal for packaging of influenza virus vectors
#67Methods for the propagation of modified influenza viruses in embryonated eggs
#68HETEROLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN
#69Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#70Human antibodies against rabies and uses thereof
#71Oral Vaccines for Fish
#72Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
#73Vaccines against vesicular stomatitis
#74Signal for packaging of influenza virus vector
#75Mutant vesicular stomatitis viruses and uses thereof
#76Compositions and methods using lentivirus-based vectors for generating immune responses
#77Lentivirus vector-based approaches for generating an immune response to HIV in humans
#78Methods and interferon deficient substrates for the propagation of viruses